Trial Profile

Randomized Trial Assessing the Significance of Bevacizumab in Recurrent Grade II and Grade III Gliomas - The TAVAREC Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 18 Jul 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Temozolomide (Primary)
Indications Astrocytoma; Glioma; Oligodendroglioma
Focus Therapeutic Use
Acronyms TAVAREC

Most Recent Events

19 Jun 2023 Results assessing the impact of the addition of BEV to TMZ on Health-related quality of life published in the European Journal of Cancer
16 Mar 2022 Results assessing prognostic significance of DNA methylation profiles at MRI enhancing tumor recurrence published in the Clinical Cancer Research
13 Aug 2018 Results published in the Lancet Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com